LOS ANGELES, June 21, 2018 /PRNewswire/ -- CytRx
Corporation (NASDAQ:CYTR), a biopharmaceutical research and
development company specializing in oncology, today highlighted
data on NantCell Inc's aldoxorubicin which was published in
the peer-reviewed journal Future Oncology. The paper,
published on June 5, 2018, is
entitled "Aldoxorubicin therapy for the treatment of patients with
advanced soft tissue sarcoma" and can be accessed online here. The
authors of the publication are Mahesh
Seetharam and Kantha R.
Kolla, both of the Division of Hematology/Oncology at the
Mayo Clinic in Phoenix, Arizona;
and Kristen N. Ganjoo, of the
Department of Medical Oncology, Stanford Cancer Institute in
Stanford, California.
The paper discusses the albumin binding mechanism of action,
pharmacokinetics, preclinical studies, clinical trial data and
safety profile of aldoxorubicin and its relevance in the future
treatment of soft tissue sarcoma. The authors emphasize that
aldoxorubicin was principally developed to increase efficacy and
overcome the cardiotoxic side effects of the anthracycline agent
doxorubicin. Phase I and Phase II studies with aldoxorubicin
demonstrated increased progression-free survival and tumor response
in the aldoxorubicin group with tolerable side effects, while the
results of a Phase III study also showed statistically significant
benefits in progression-free survival in leiomyosarcoma and
liposarcoma subgroups. The authors conclude that the unique
biochemical structure of aldoxorubicin causes its target-specific
drug delivery property, which, in combination with its negligible
levels of cardiotoxicity even at high doses, should give
aldoxorubicin a meaningful role in the treatment of patients with
metastatic soft tissue sarcoma, as an adjuvant therapy in sarcomas,
or as a treatment for patients who have other anthracycline
sensitive tumor types.
"The publication of this data in Future Oncology
underscores aldoxorubicin's benefit over doxorubicin in providing
both a meaningful and clinical benefit to patients with soft tissue
sarcoma while avoiding the cardiotoxicity that is the main
limitation with doxorubicin usage," said Eric Curtis, CytRx's President and Chief
Operating Officer. "Early and late phase studies of aldoxorubicin
have shown improved response rates and, due to modifications in its
biochemical structure, an acceptable toxicity profile. We look
forward to NantCell's further clinical development of aldoxorubicin
in soft tissue sarcoma and other types of cancer with very high
unmet needs."
CytRx out-licensed global development, manufacturing, and
commercialization rights for aldoxorubicin to NantCell, Inc., a
private subsidiary of NantWorks, LLC, in July 2017.
About CytRx Corporation
CytRx Corporation (Nasdaq: CYTR) is a biopharmaceutical company
with expertise in discovering and developing new therapeutics to
treat patients with cancer. CytRx's wholly owned subsidiary,
Centurion BioPharma Corporation, is focused on advancing a
portfolio of novel, anti-cancer drug candidates that employ its
LADR™ (Linker Activated Drug Release) technology, a discovery
engine designed to leverage Centurion's expertise in albumin
biology and linker technology for the development of a new class of
potential breakthrough anti-cancer therapies. A critical element of
the LADR™ platform is its ability to bind anti-cancer molecules to
albumin, the most ubiquitous protein in human blood plasma, and
then to release the highly potent cytotoxic payload at the tumor
site. This technology allows for the delivery of higher doses of
drug directly to the tumor, while avoiding much of the off-target
toxicity observed with the parent molecules. CytRx's most advanced
drug conjugate, aldoxorubicin, is an improved version of the widely
used anti-cancer drug doxorubicin and has been out-licensed to
NantCell, Inc.
Forward-Looking Statements
This press release contains forward-looking statements. Such
statements involve risks and uncertainties that could cause actual
events or results to differ materially from the events or results
described in the forward-looking statements, including risks and
uncertainties relating to the ability of NantCell, Inc., to obtain
regulatory approval for its products that use aldoxorubicin; the
ability of NantCell, Inc., to manufacture and commercialize
products or therapies that use aldoxorubicin; the amount, if any,
of future milestone and royalty payments that we may receive from
NantCell, Inc.; Centurion BioPharma Corporation's ability to
develop new ultra-high potency drug candidates based on its LADR™
technology platform; our ability to attract potential licensees;
and other risks and uncertainties described in the most recent
annual and quarterly reports filed by CytRx with the Securities and
Exchange Commission and current reports filed since the date of
CytRx's most recent annual report. All forward-looking statements
are based upon information available to CytRx on the date the
statements are first published. CytRx undertakes no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.
Investor Relations Contact:
Argot Partners
Michelle Carroll
(212) 600-1902
michelle@argotpartners.com
View original
content:http://www.prnewswire.com/news-releases/cytrx-corporation-highlights-review-of-nantcell-incs-aldoxorubicin-published-in-future-oncology-300669957.html
SOURCE CytRx Corporation